Table 1.
Summary of phase 3 trials of immunotherapy in gastric cancer.
| Trial | Setting | Interventional Arm | Comparator | Outcomes | Comments |
|---|---|---|---|---|---|
| ATTRACTION-2 | Chemo-refractory | nivoluab | placebo | Positive for OS | - |
| Keynote-061 | 2nd line | pembrolizumab | taxol | No difference for OS | Potential benefit in CPS ≥ 10 |
| JAVELIN Gastric 300 | 3rd line | avelumab | Taxanes/irinotecan | No difference for OS | - |
| Keynote-062 | 1st line | pembro or pembro+ chemo | Platinum chemo +placebo | Pembro non inferior to chemo in CPS ≥ 1 | Pembro numerically superior to chemo in CPS ≥ 10 |
| JAVELIN Gastric 100 | 1st line maintenance | avelumab after chemo induction | Chemotherapy continuation | No difference for OS | Avelumab numerically superior in CPS (+) |
| Checkmate-649 | 1st line (CPS ≥ 5) | nivo+ chemo or nivo-ipi | Platinum chemo | Nivo+chemo superior OS in CPS ≥ 5 | Nivo-ipi: no difference for OS |
| ATTRACTION-4 | 1st line (Asian population) | Nivo + chemo | Platinum chemo + placebo | Nivo+ chemo superior for PFS regardless of PD-L1 expression | No difference in OS |
| ORIENT-16 | 1st line in CPS ≥ 5 (Asian population) | Sintilimab + chemo | Platinum chemo + placebo | Sintilimab + chemo superior for OS in CPS ≥ 5 and all randomized patients | - |
| Keynote-811 | 1st line HER2 positive | Pembro+trastuzumab + chemo | placebo+trastuzumab + chemo | Pembro arm superior for ORR | Very preliminary data |